Later lines in pMMR/MSS metastatic colorectal cancer: News opportunities with immunotherapy and local treatments

키워드

참고문헌 (62)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Grothey A, "Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.303~312 (2013)
3. Li J, "Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer : the FRESCO randomized clinical trial", JAMA, 319, pp.2486~2496 (2018)
4. Xu J, "Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine", tipiracil(TAS102)monotherapy in Asian patients with previously treated metastatic colorectal cancer : the TERRA study, 2018, pp.36, 350~358
5. Cohen R, "Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status", JAMA Oncol, 5, pp.551~555 (2019)
6. Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142) : an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
7. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
8. Fukuoka S, "Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer : an open-label, dose-escalation, and dose-expansion phase Ib trial(REGONIVO, EPOC1603)", J Clin Oncol, 38, pp.2053~2061 (2020)
9. Zhang W, "423P Fruquintinib plus sintilimab in refractory repair-proficient(pMMR)", microsatellite stable(MSS)metastatic colorectal cancer(mCRC) : preliminary clinical results and biomarker analyses from a phase II study, 2022, pp.33(Suppl 7), S728~
10. Gomez-Roca C, "LEAP005 : a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort", J Clin Oncol, 39(3 Suppl), pp.94~ (2021)
11. Saeed A, "Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies : phase Ib CAMILLA trial results", Cell Rep Med, 4, pp.100916~ (2023)
12. Fakih M, "Singlearm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient(pMMR)", microsatellite stable(MSS)colorectal cancer(CRC), 2021, pp.39(15 Suppl), 3560~
13. Fakih M, "Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy : a phase 1 nonrandomized clinical trial", JAMA Oncol, 9, pp.627~634 (2023)
14. Wang F, "Regorafenib plus toripalimab in patients with metastatic colorectal cancer : a phase Ib", II clinical trial and gut microbiome analysis, 2021, pp.2, 100383~
15. Cousin S, "Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer(regomune) : a single-arm, open-label, phase II trial", Clin Cancer Res, 27, pp.2139~2147 (2021)
16. Chen J, "Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma(HCC)in BCLC stage B and C : a prospective, single-arm, phase II trial(Cal Era study)", J Clin Oncol, 41(16 Suppl), pp.e16128~ (2023)
17. de la Torre-Aláez M, "Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma : a phase 2, single-arm study", J Immunother Cancer, 10, pp.e005457~ (2022)
18. Lumniczky K, "The impact of radiation therapy on the antitumor immunity : local effects and systemic consequences", Cancer Lett, 356, pp.114~125 (2015)
19. Marincola FM, "Escape of human solid tumors from T-cell recognition : molecular mechanisms and functional significance", Adv Immunol, 74, pp.181~273 (2000)
20. Zebertavage LK, "Transcriptional upregulation of NLRC5 by radiation drives STING-and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity", Sci Rep, 10, pp.7376~ (2020)
21. Zhang B, "Induced sensitization of tumor stroma leads to eradication of established cancer by T cells", J Exp Med, 204, pp.49~55 (2007)
22. Formenti SC, "Radiation therapy to convert the tumor into an in situ vaccine", Int J Radiat Oncol Biol Phys, 84, pp.879~880 (2012)
23. Lomax ME, "Biological consequences of radiation-induced DNA damage : relevance to radiotherapy", Clin Oncol(R Coll Radiol), 25, pp.578~585 (2013)
24. Klug F, "Low-dose irradiation programs macrophage differentiation to an iNOS+", M1 phenotype that orchestrates effective T cell immunotherapy, 2013, pp.24, 589~602
25. Deng L, "Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice", J Clin Invest, 124, pp.687~695 (2014)
26. Du SS, "Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation", Int J Radiat Oncol Biol Phys, 112, pp.1243~1255 (2022)
27. Moore C, "Personalized ultrafractionated stereotactic adaptive radiotherapy(PULSAR)in preclinical models enhances single-agent immune checkpoint blockade", Int J Radiat Oncol Biol Phys, 110, pp.1306~1316 (2021)
28. Olivo Pimentel V, "Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy", J Immunother Cancer, 9, pp.e001764~ (2021)
29. Yu J, "Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination", Nat Med, 27, pp.152~164 (2021)
30. Persa E, "The effect of ionizing radiation on regulatory T cells in health and disease", Cancer Lett, 368, pp.252~261 (2015)
31. Jin M, "Abstract LB302 : radiotherapy exposure and baseline gut microbiota predict clinical outcomes of fruquintinib plus sintilimab in microsatellite-stable metastatic colorectal cancer", Cancer Res, 83(8 Suppl), pp.LB302~ (2023)
32. Lin Z, "Efficacy and safety of radiation therapy combined with anti-angiogenic agents and immunotherapy for MSS", pMMR metastatic colorectal cancer : a real-world study, 2023, pp.41(16 Suppl), e15559~
33. Parikh AR, "Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial", Nat Cancer, 2, pp.1124~1135 (2021)
34. Koenig JL, "A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer", J Clin Oncol, 41(16 Suppl), pp.3584~ (2023)
35. Yang J, "The response of PD-1 inhibitor combined with Radiotherapy and GM-CSF(PRaG)with or without IL-2 in microsatellite stable metastatic colorectal cancer : analysis of pooled data from two phase II trials", J Clin Oncol, 40(16 Suppl), pp.e15561~ (2022)
36. Yuan X, "Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability(MSS)metastatic colorectal cancer(mCRC) : results from the FRUIT trial", J Clin Oncol, 41(16 Suppl), pp.150~ (2023)
37. Margalit O, "Combination treatment of intratumoral vidutolimod, radiosurgery, nivolumab, and ipilimumab for microsatellite stable colorectal carcinoma with liver metastases", Clin Colorectal Cancer, 22, pp.442~449 (2023)
38. Segal NH, "Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer", Clin Cancer Res, 27, pp.2200~2208 (2021)
39. Wang C, "Abstract 528 : radioembolization followed by durvalumab and tremelimumab does not induce immune responses against liver-metastasized MSS colorectal cancer", Cancer Res, 79(13 Suppl), pp.528~ (2019)
40. Duffy AG, "A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy(SBRT)in patients with metastatic colorectal cancer", J Clin Oncol, 34(4 Suppl), pp.560~ (2016)
41. Yuki S, "Short-term results of VOLTAGE-A : nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer", J Clin Oncol, 38(15 Suppl), pp.4100~ (2020)
42. Salvatore L, "Phase II study of preoperative(PREOP)chemoradiotherapy(CTRT)plus avelumab(AVE)in patients(PTS)with locally advanced rectal cancer(LARC) : the AVANA study", J Clin Oncol, 39(15 Suppl), pp.3511~ (2021)
43. George TJ, "NRG-GI002 : a phase II clinical trial platform using total neoadjuvant therapy(TNT)in locally advanced rectal cancer(LARC)—first experimental arm(EA)initial results", J Clin Oncol, 37(15 Suppl), pp.3505~ (2019)
44. den Brok MH, "In situ tumor ablation creates an antigen source for the generation of antitumor immunity", Cancer Res, 64, pp.4024~4029 (2004)
45. Chu KF, "Thermal ablation of tumours : biological mechanisms and advances in therapy", Nat Rev Cancer, 14, pp.199~208 (2014)
46. Wissniowski TT, "Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits", Cancer Res, 63, pp.6496~6500 (2003)
47. Rai R, "Study of apoptosis and heat shock protein(HSP)expression in hepatocytes following radiofrequency ablation(RFA)", J Surg Res, 129, pp.147~151 (2005)
48. Liu GJ, "Expression of heat shock protein 70 in rabbit liver after contrast-enhanced ultrasound and radiofrequency ablation", Ultrasound Med Biol, 36, pp.78~85 (2010)
49. Troy AJ, "Minimal recruitment and activation of dendritic cells within renal cell carcinoma", Clin Cancer Res, 4, pp.585~593 (1998)
50. Dromi SA, "Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity", Radiology, 251, pp.58~66 (2009)
51. Shi L, "PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor", Clin Cancer Res, 22, pp.1173~1184 (2016)
52. Segal NH, "Nonrandomized phase II study to assess the efficacy of pembrolizumab(Pem)plus radiotherapy(RT)or ablation in mismatch repair proficient(pMMR)metastatic colorectal cancer(mCRC)patients", J Clin Oncol, 34(15 Suppl), pp.3539~ (2016)
53. Seligmann JF, "Durvalumab and tremelimumab plus local tumor ablation(RFA or stereotactic radiotherapy)in patients with metastatic colorectal cancer with unresectable liver metastases : results of the EORTC-1560-GITCG(ILOC)phase II study", J Clin Oncol, 41(4 Suppl), pp.141~ (2023)
54. Li J, "The efficacy and safety of regorafenib in combination with anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer : a retrospective study", Front Oncol, 10, pp.594125~ (2020)
55. Ren Z, "Changes in the peripheral blood Treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles", Front Immunol, 12, pp.624789~ (2021)
56. Ayaru L, "Unmasking of alpha-fetoprotein-specific CD4+T cell responses in hepatocellular carcinoma patients undergoing embolization", J Immunol, 178, pp.1914~1922 (2007)
57. Hickey RM, "Immunooncology and its opportunities for interventional radiologists : immune checkpoint inhibition and potential synergies with interventional oncology procedures", J Vasc Interv Radiol, 28, pp.1487~1494 (2017)
58. Wigg AJ, "Radiotherapy for hepatocellular carcinoma : systematic review of radiobiology and modeling projections indicate reconsideration of its use", J Gastroenterol Hepatol, 25, pp.664~671 (2010)
59. Gameiro SR, "Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens", Oncoimmunology, 3, pp.e28643~ (2014)
60. Zhu HD, "Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)", Signal Transduct Target Ther, 8, pp.58~ (2023)
61. Cao F, "Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens", J Cancer Res Clin Oncol, 147, pp.2993~3002 (2021)
62. Cao G, "A retrospective study of local hepatic artery infusion chemotherapy combined with regorafenib in the treatment of advanced colorectal cancer with predominant liver metastases", J Clin Oncol, 39(15 Suppl), pp.e15563~ (2021)

관련 논문AI추천